



# ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006  
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad  
E-mail : [ishitadrugs@gmail.com](mailto:ishitadrugs@gmail.com) | [info@ishitadrugs.com](mailto:info@ishitadrugs.com) | URL : [www.ishitadrugs.com](http://www.ishitadrugs.com)

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Date: 23.11.2024

To,  
Department of Corporate Services,  
BSE Limited.  
Floor No. 25, Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400 001

**Scrip Code: 524400**

Dear Sir/Madam,

**Sub: Disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

With Reference to the captioned subject, please find enclosed the disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011:

- a) Acquisition of 500 shares of Rs. 10/- each by Abha Agrawal, Promoter.

Please take the above disclosure on record.

Thanking You,

For, Ishita Drugs and Industries Limited

Jagdish Agrawal  
Managing Director

*"Our basic drugs in the service of humanity worldwide"*

CIN No. L24231GJ1992PLC017054  
D & B D-U-N-S Number - 65-018-0359

Date: 22.11.2024

To,  
Department of Corporate Services,  
BSE Limited.  
Floor No. 25, Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400 001

**Ishita Drugs & Industries Ltd.**  
Office No: 401, 3<sup>rd</sup> Eye II,  
Opp. Parimal Garden, C.G. Road,  
Ahmedabad – 380 006

**Scrip Code: 524400**

Dear Sir/Madam,

**Sub: Disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares & takeovers) Regulations, 2011**

With Reference to the captioned subject, I, Abha Agrawal, Promoter of Ishita Drugs and Industries Limited hereby inform you that I have acquired 500 shares of Rs. 10/- each of Ishita Drugs & Industries Ltd. on 21<sup>st</sup> November, 2024.

Please find enclosed the necessary disclosure as required under regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Kindly, take the above information on your record.

Thanking you,

Yours Faithfully,

  
Abha Agrawal

**Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company (TC)	<b>Ishita Drugs and Industries Limited</b>		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<b>Abha Agrawal</b>		
Whether the acquirer belongs to Promoter/Promoter group	<b>Promoter</b>		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	<b>BSE Limited</b>		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of :</b>			
a) Shares carrying voting rights	<b>250296</b>	<b>8.37</b>	<b>8.37</b>
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
c) Voting rights (VR) otherwise than by shares	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
e) Total (a+b+c+d)	<b>250296</b>	<b>8.37</b>	<b>8.37</b>
<b>Details of acquisition</b>			
a) Shares carrying voting rights acquired/sold	<b>500</b>	<b>0.02</b>	<b>0.02</b>
b) VRs acquired /sold otherwise than by shares	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
d) Shares encumbered / invoked/released by the acquirer	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
e) Total (a+b+c+d)	<b>500</b>	<b>0.02</b>	<b>0.02</b>


AA

<b>After the acquisition, holding of:</b>			
a) Shares carrying voting rights	<b>250796</b>	<b>8.39</b>	<b>8.39</b>
b) Shares encumbered with the acquirer	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>
c) VRs otherwise than by shares	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>
e) Total (a+b+c+d)	<b>250796</b>	<b>8.39</b>	<b>8.39</b>
Mode of acquisition	Open Market		
Date of acquisition	November 21, 2024		
Equity share capital of the Target Company before the said acquisition	Rs. 29903000/- (2990300 shares of Rs.10 each)		
Equity share capital of the Target Company after the said acquisition	Rs. 29903000/- (2990300 shares of Rs.10 each)		
Total diluted share/voting capital of the Target Company after the said acquisition	Rs. 29903000/- (2990300 shares of Rs.10 each)		

(\* ) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

**Signature of the acquirer**

  
**Abha Agrawal**  
**Promoter**